Nitrogen-containing polyhydroxylated aromatics as HIV-1 integrase inhibitors: Synthesis, structure-activity relationship analysis, and biological activity

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 27, Issue 5, 2012, Pages 628-640

  Yu, Shenghui ^a   Zhang, Linna ^b   Yan, Shifeng ^a   Wang, Peng ^a   Sanchez, Tino ^c   Christ, Frauke ^d   Debyser, Zeger ^d   Neamati, Nouri ^c   Zhao, Guisen ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

Author keywords

HIV 1; Integrase inhibitors; Polyhydroxylated aromatics; Structure activity relationship

Indexed keywords

3 (3,4 DIHYDROXYPHENYL) N (2,3,4 TRIFLUOROPHENYLSULFAMOYL)PHENYL)ACRYLAMIDE; 3 (3,4 DIHYDROXYPHENYL) N (4 (2 BROMOPHENYLSULFAMOYL)PHENYL)ACRYLAMIDE; 3 (3,4 DIHYDROXYPHENYL) N (4 (3 BROMOPHENYLSULFAMOYL)PHENYL)ACRYLAMIDE; 3 (3,4 DIHYDROXYPHENYL) N (4 (3,4 DICHLOROPHENYLSULFAMOYL)PHENYL)ACRYLAMIDE; 3 (3,4 DIHYDROXYPHENYL) N (4 (3,4 DIFLUOROPHENYLSULFAMOYL)PHENYL)ACRYLAMIDE; 3 (3,4 DIHYDROXYPHENYL) N (4 (4 BROMOPHENYLSULFAMOYL)PHENYL)ACRYLAMIDE; 3 (3,4 DIHYDROXYPHENYL) N (4 (4 BUTYLPHENYLSULFAMOYL)PHENYL)ACRYLAMIDE; 3 (3,4 DIHYDROXYPHENYL) N (4 (4 FLUOROBENZYLSULFAMOYL)PHENYL)ACRYLAMIDE; 3 (3,4 DIHYDROXYPHENYL) N (4 (4 FLUOROPHENYLSULFAMOYL)PHENYL)ACRYLAMIDE; CAFFEIC ACID PHENETHYL ESTER; INTEGRASE INHIBITOR; N (4 (2,3,4 TRIFLUOROPHENYLSULFAMOYL)PHENYL)GALLOYLAMIDE; N (4 (3 BROMOPHENYLSULFAMOYL)PHENYL)GALLOYLAMIDE; N (4 (3,4 DIFLUOROPHENYLSULFAMOYL)PHENYL)GALLOYLAMIDE; N (4 (4 BROMOPHENYLSULFAMOYL)PHENYL)GALLOYLAMIDE; N (4 (4 FLUOROBENZYLSULFAMOYL)PHENYL)GALLOYLAMIDE; N (4 (4 FLUOROPHENYLSULFAMOYL)PHENYL)GALLOYLAMIDE; NITROGEN; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

CELL LINE; HIV; HIV INTEGRASE INHIBITORS; HUMANS; HYDROXYLATION; INHIBITORY CONCENTRATION 50; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; NITROGEN; POLYCYCLIC COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84866094356     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2011.604851     Document Type: Article

References (19)

1. De Clercq E. New approaches toward anti-HIV chemotherapy. J Med Chem 2005;48:1297-1313. (Pubitemid 40364540)
2. Geffen N. Beyond HAART: scientists and activists need to work together. Lancet 2009;374:860-861.
3. Dayam R, Gundla R, Al-Mawsawi LQ, Neamati N. HIV-1 integrase inhibitors: 2005-2006 update. Med Res Rev 2008;28:118-154. (Pubitemid 350274962)
4. Zhao G, Wang C, Liu C, Lou H. New developments in diketocontaining inhibitors of HIV-1 integrase. Mini Rev Med Chem 2007;7:707-725. (Pubitemid 47099172)
5. Johnson AA, Marchand C, Pommier Y. HIV-1 integrase inhibitors: A decade of research and two drugs in clinical trial. Curr Top Med Chem 2004;4:1059-1077. (Pubitemid 38854857)
6. Fesen MR, Kohn KW, Leteurtre F, Pommier Y. Inhibitors of human immunodeficiency virus integrase. Proc Natl Acad Sci usa 1993;90:2399-2403. (Pubitemid 23078634)
7. Ho CC, Lin SS, Chou MY, Chen FL, Hu CC, Chen CS et al. Effects of CAPE-like compounds on HIV replication in vitro and modulation of cytokines in vivo. j Antimicrob Chemother 2005;56:372-379.
8. Neamati N, Lin Z, Karki RG, Orr A, Cowansage K, Strumberg D et al. Metal-dependent inhibition of HIV-1 integrase. J Med Chem 2002;45:5661-5670. (Pubitemid 35453759)
9. Tchertanov L, Mouscadet JF. Target recognition by catechols and betaketoenols: Potential contribution of hydrogen bonding and Mn/Mg helation to HIV-1 integrase inhibition. j Med Chem 2007;50:1133-1145. (Pubitemid 46496314)
10. Zhao H, Neamati N, Mazumder A, Sunder S, Pommier Y, Burke TR Jr. Arylamide inhibitors of HIV-1 integrase. J Med Chem 1997;40:1186-1194. (Pubitemid 27175097)
11. King PJ, Ma G, Miao W, Jia Q, McDougall BR, Reinecke MG et al. Structure-activity relationships: Analogues of the dicaffeoylquinic and dicaffeoyltartaric acids as potent inhibitors of human immunodeficiency virus type 1 integrase and replication. J Med Chem 1999;42:497-509. (Pubitemid 29085110)
12. Supuran CT, Innocenti A, Mastrolorenzo A, Scozzafava A. Antiviral sulfonamide derivatives. Mini Rev Med Chem 2004;4:189-200. (Pubitemid 38854865)
13. Fisher TE, Kim B, Staas DD, Lyle TA, Young SD, Vacca JP et al. 8-Hydroxy-3,4-dihydropyrrolo[1,2-a]pyrazine-1(2H)-one HIV-1 integrase inhibitors. Bioorg Med Chem Lett 2007;17:6511-6515. (Pubitemid 350026333)
14. Marchand C, Maddali K, Métifiot M, Pommier Y. HIV-1 IN inhibitors: 2010 update and perspectives. Curr Top Med Chem 2009;9:1016-1037.
15. Serrao E, Odde S, Ramkumar K, Neamati N. Raltegravir, elvitegravir, and metoogravir: The birth of "me-too" HIV-1 integrase inhibitors. Retrovirology 2009;6:25.
16. Lee-Huang S, Huang PL, Zhang D, Lee JW, Bao J, Sun Y et al. Discovery of small-molecule HIV-1 fusion and integrase inhibitors oleuropein and hydroxytyrosol: Part II. integrase inhibition. Biochem Biophys Res Commun 2007;354:879-884. (Pubitemid 46216215)
17. Wu B, Zhou L, Cai HH. Synthesis and neuroprotective properties of novel cinnamide derivatives. Chinese Chem Lett 2008;19:1163-1166.
18. Andrus MB, Liu J, Meredith EL, Nartey E. Synthesis of resveratrol using a direct decarbonylative Heck approach from resorcylic acid. Tetrahedron Lett 2003;44:4819-4822. (Pubitemid 36694244)
19. Dayam R, Al-Mawsawi LQ, Zawahir Z, Witvrouw M, Debyser Z, Neamati N. Quinolone 3-carboxylic acid pharmacophore: design of second generation HIV-1 integrase inhibitors. J Med Chem 2008;51:1136-1144. (Pubitemid 351480377)